I’m praying you can find a gene cure for Anders Payne’s eyes! One of my beloved grandsons. ❤️❤️❤️

Odylia Therapeutics is a nonprofit biotech working to accelerate the development of treatments for people with rare diseases.

At Odylia, we accelerate therapeutic development for people with rare diseases, changing the way treatments are brought from the lab to the clinic. We strive to bring life altering treatments to people with genetic disease regardless of prevalence or commercial interest. 
Odylia is shifting the paradigm to focus on proven science and removing traditional roadblocks. We work to lower costs, reduce development time, focus research, and continuously drive successful programs towards clinical trials and regulatory approval. Strategic collaborations with patient groups, research labs, and commercial partners facilitate our work to ensure treatments are safe, effective, and ultimately reach patients who need them.

Odylia challenges the traditional approach to drug development through:

1. Lower cost of development
Lower licensing fees to decrease development costs and ensure continued commitment to program success

2. Increase speed of development
Challenge traditional approaches through regulatory engagement

Streamline development through strategic partnerships and a platform approach to drug development

3. Enable the entire ecosystem
Provide expertise through in-house Brydge Solutions and leveraging the Odylia Board

Enable the entire ecosystem through Initiatives that impact the broader field

Odylia Therapeutics

Join us in supporting nonprofits working with Youth.

Youth

Humans

Research

Health

Discover nonprofits supporting disease prevention.

Join us in supporting nonprofits working on disease prevention.

Disease Prevention

Discover nonprofits supporting science and technology.

Join us in supporting science and technology nonprofits.

Science & Technology

1258415673

1435915265

1737023302

We are a nonprofit, so instead of charging fees we rely on the generosity of donors like you.

Choose a donation for Every.org

2074652487

240751341

2516130445

2624895975

2883383521

339774024

3605944885

3755280456

3794356679

3868271524

3884515653

410756082

579816602

761293274

772217036

2729980760

3440869557

671754822

1014384873

1112422858

153399038

2028390811

220342792

2266630408

2456389719

2519810400

2539558839

2826465835

2843798242

2898624300

2916352438

3259439560

3583328878

3642494300

3902459442

4054861980

4136002033

4177183036

4250940449

585491400

641510716

91682487

As many of you know, our sweet Anders has a rare genetic eye condition called Leber Congenital Amaurosis (LCA), which is a severe type of cone rod dystrophy. This condition is not only rare but also progressively degenerative, threatening Anders’ vision and overall quality of life.

There are several different genes associated with LCA, but the specific gene mutation that affects Anders currently has no treatment. In our search for hope and a potential cure, we learned about Odylia, an 501(c)3 organization that is making remarkable strides in the field of gene therapy specifically targeting the gene that affects Anders’ eyesight. 

While we are excited by the progress, the reality is that funding for rare diseases is much harder to come by, and grassroots efforts make a big difference in keeping the research moving forward. We humbly request your financial support to aid Odylia in continuing their critical research and development efforts. 

We understand that there are many causes worthy of support, so we would be incredibly grateful if you could contribute whatever amount you can. Your generosity will not only support cutting-edge research but also provide hope and encouragement to families like ours who are eagerly waiting for a breakthrough.

Thank you for considering our request. 

With sincere gratitude,

Joe and Kim Payne

Help Find a Cure for Anders' Eyesight 

Dylan is one of the smartest, wittiest, and happiest 4 year olds you would ever meet. She loves gymnastics, music, learning, skiing, swimming, riding her bike without training wheels, running, Peppa Pig, and reading books in both braille and large print. When Dylan was about 2 months old, we noticed that she had nystagmus. Three months later, through many doctors appointments and genetic testing, we learned that Dylan has Lebers Congenital Amaurosis (LCA). As of now, Dylan has enough functional vision that at close distances she can identify shapes, letters, colors, and familiar faces. Since she is still young, it is unknown at what degree of clarity she can see these things. What we do know, is that LCA is a degenerative condition, meaning Dylan’s vision is likely to deteriorate even further as she gets older. As her parents, we are hopeful that before her vision significantly deteriorates, that a gene therapy treatment will become available to preserve, or possible even improve her vision. The data, research and groundwork are all in place for this to happen. We just need funding to help support Odylia in getting this project to clinical trials. This could be reality in two short years if fundraising goals are met. You could help change the future for Dylan and many others just like her!

Help Save Dylan’s Vision

Freya is happy 7 year old, she enjoys horse riding, baking, and building her Lego sets just like all other little girls do. What you wouldn’t realise about Freya unless you really took notice is that she is registered severely sight impaired. We realised there was a problem with Freya’s vision when she was 6 weeks old and she was diagnosed with Lebers Congenital Amaurosis when she was 6 months old, The last 6 and a half years have been a steep learning curve for us all, full of challenges and adaptations to help Freya along the way. There have been both amazing highs and devastating lows for us all. Unlike many children with her condition, she has some useful vision left for now and we are thankful that with a little help she has been able to see the things we often take for granted. However, Lebers is a degenerative condition so very sadly in the near future her vision is likely to decline even further. As her parents we cling on to the hope that before this decline happens a treatment will become available to allow her to retain the vision she has. The treatment will not restore her vision, but rather keep it at the level it is. There is limited funding in this area, but we are now aware of a research project into Freya’s gene that may one day be the answer to our prayers. As always we are extremely grateful for everyone that has helped us raise money along the way, and for every penny people have donated. We continue to do our best to help fund the research project, in the hope that one day we will find a cure for Freya and others alike, Gav & Paula Birch Freya’s very proud parents

Odylia Therapeutics is a charity developing a gene therapy to treat vision loss caused by RPGRIP1 mutations, for which there is currently no treatment. Odylia partners with patients, families, and researchers all over the world to accelerate therapeutic development and is currently conducting late-stage preclinical experiments and is preparing for IND submission for use of the gene therapy in clinical trials. 

Odylia’s focus starts and ends with patients. We are committed to changing the future for families affected by rare disease around the world. YOU can help bring promising treatments to patients. You can donate from this page - donations are made in USD ($) but then will be converted converted on the backend to GBP which you will see on your statement after the transaction.

At Odylia, we accelerate therapeutic development for people with rare diseases, changing the way treatments are brought from the lab to the clinic. We strive to bring life altering treatments to people with genetic disease regardless of prevalence or commercial interest. Odylia is shifting the paradigm to focus on proven science and removing traditional roadblocks. We work to lower costs, reduce development time, focus research, and continuously drive successful programs towards clinical trials and regulatory approval. Strategic collaborations with patient groups, research labs, and commercial partners facilitate our work to ensure treatments are safe, effective, and ultimately reach patients who need them.

SAVING FREYA’S SIGHT

Odylia Therapeutics

Fundraisers

Donors

.css-1d3w5wq{width:100%;}.css-yi15dt{display:inline-block;--textSize:2rem;--lineHeight:2.4rem;line-height:var(--lineHeight);font-size:var(--textSize);width:100%;}Odylia Therapeutics

Fundraisers

Donors

Odylia Therapeutics